Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene
โ Scribed by P. Vestergaard; F. Schwartz; L. Rejnmark; L. Mosekilde
- Publisher
- Springer-Verlag
- Year
- 2010
- Tongue
- English
- Weight
- 184 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0937-941X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Abstract Subtrochanteric and femoral shaft (ST/FS) fractures are now considered to be fragility fractures in osteoporotic patients. Although rare, there is growing evidence of the burden that they constitute. Little is known about the change over time in incidence of ST/FS fractures. We assessed
Bisphosphonates are the primary therapy for postmenopausal and glucocorticoid-induced osteoporosis. Case series suggest a potential link between prolonged use of bisphosphonates and low-energy fracture of subtrochanteric or diaphyseal femur as a consequence of oversuppression of bone resorption. Usi
Increasing numbers of atypical hip fractures have been reported among patients with bisphosphonate use. However, the nature and extent of the problem are unknown despite recent investigations. To analyze national trends in hip fractures and medication use in the elderly US population, we respectivel